Posted by Michael Wonder on 11 Dec 2023
FDA accepts for review resubmitted NDA for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism
11 December 2023 - PDUFA goal date is 14 May 2024.
Ascendis Pharma today announced that the US FDA has accepted for review the Company’s resubmitted new drug application for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism.
